Home » News » Gene Therapy for β-Thalassaemia Approaches European Market Approval

Gene Therapy for β-Thalassaemia Approaches European Market Approval

Gene therapy continues to evolve with new emerging treatments finally reaching its promised potential: providing a one-time lifelong cure for even the rarest and most severe of genetic disorders.

TIF’s Expert Advisor, Dr. Carsten Werner Lederer, explores this critical issue in his article, by highlighting the recent conditional approval for the first universal cure for the clinically most significant type of thalassaemia, β-thalassaemia.

Read the full article Read Bluebird Bio’s press release on Zynteglo